Hot topics | Coronavirus pandemic

French Company Sanofi Is Close To An Agreement To Supply The EU With 300 Million Doses Of COVID-19 Vaccine

French Company Sanofi Is Close To An Agreement To Supply The EU With 300 Million Doses Of COVID-19 Vaccine

French company Sanofi is close to an agreement to supply the EU with 300 million doses of COVID-19 vaccine.

French pharmaceutical company Sanofi is close to signing an agreement with the EU to supply 300 million doses of a potential vaccine for the coronavirus COVID-19, according to French TV channel BFM-TV.

"We are in very advanced negotiations with the European Union," said Olivier Bogillot, France's president of the pharmaceutical group, without giving further details about this agreement that could be finalized "in the coming days or weeks."

Discussions with several countries

The leader also indicated that he is in talks with the United States and the United Kingdom, as well as collaborating with the Global Alliance for vaccines and vaccinations, without detailing how many doses could be reserved for each state. "Our goal is to work with all states to ensure that this vaccine is distributed to all and simultaneously," explains Olivier Bogillot.

Sanofi had created a heated controversy in May when its CEO Paul Hudson had raised the possibility of favoring the United States for the distribution of a possible vaccine, after funding from Washington. The French laboratory is currently developing two vaccines, based on two different technologies, against Covid-19. The one covered by the agreement with the European Union-developed with the British GSK -, uses the so-called recombinant DNA technology, already used for a flu vaccine. It is expected to undergo clinical trials in September and be available in the first half of 2021. The group says it can produce up to one billion doses per year.

Doses produced in Europe

For Europeans, doses will be produced in Europe, and in particular at several Sanofi sites in France, says Olivier Bogillot. Several laboratories have already concluded such agreements. In this way, pharmaceutical companies, which invest in particular to prepare their production tool without knowing whether the potential vaccine will ever materialize, limit the financial risk involved in the operation. In return, the contributing countries secure a supply, while the competition for access to a vaccine is global.

At the key, this arrangement offers "visibility" so that pharmaceutical groups "can organize their production," commented Agnes Pannier-Runacher, Minister Delegate for the industry. Producing a vaccine of this magnitude "can lead to reinvestment at certain sites" in France and Europe, she also argued.